Keyphrases
Murine Model
100%
Chemoimmunotherapy
100%
Hepatocellular Cancer
100%
Tumor
42%
Programmed Death-ligand 1 (PD-L1)
42%
Sunitinib
42%
Mouse Model
28%
Clinically Significant
28%
Tumor Progression
28%
Treg
28%
Antigen-specific CD8+ T Cells
28%
Tumor Growth
14%
Cancer Patients
14%
Hepatocytes
14%
Immune System
14%
Immune Tolerance
14%
Nave
14%
Immunodeficient Mice
14%
Circulating Tumor Cells
14%
Host Immunity
14%
Tumor Immunity
14%
CD8+ T Cells
14%
Antitumor
14%
Cell Tumor
14%
Intraperitoneal Injection
14%
Inoculation
14%
Aggressive Tumor
14%
Regulatory T Cells
14%
Lay Summary
14%
Immune-competent
14%
Tumor-draining Lymph Nodes
14%
Antigen-specific Immune Response
14%
Tumor Antigen
14%
Between-host
14%
Cancer Progression
14%
Cancer Initiation
14%
Immunization
14%
Antibody-mediated
14%
Tumor Migration
14%
Tyrosine Kinase Inhibitor
14%
Tumoricidal Activity
14%
Tumor Control
14%
Anti-PD-1 Antibody
14%
Early Tumor
14%
Carbon Tetrachloride
14%
Adoptive Cell Transfer
14%
Typical Features
14%
Fibrotic Liver
14%
Treg Suppression
14%
Human Liver Cancer
14%
Immunology and Microbiology
Regulatory T Cell
100%
Cytotoxic T-Cell
75%
Tumor Antigen
75%
Sunitinib
75%
Mouse Model
50%
Immunology
50%
Immune Tolerance
25%
Immune Response
25%
Immune System
25%
Immunity
25%
Programmed Death 1 Receptor
25%
Tumor Immunity
25%
Upregulation
25%
Transfer Cell
25%
Immunotherapy
25%
Lymph Node
25%
Cancer Staging
25%
Circulating Tumor Cell
25%
Medicine and Dentistry
Malignant Neoplasm
100%
Chemoimmunotherapy
100%
Neoplasm
37%
Tumor Progression
37%
Tumor Antigen
37%
Sunitinib
37%
Cytotoxic T-Cell
37%
Immunity
12%
Metastatic Carcinoma
12%
Immune Response
12%
Upregulation
12%
Lymph Node
12%
Immune System
12%
Circulating Tumor Cell
12%
Hepatocyte
12%
Liver Cancer
12%
Tyrosine-Kinase Inhibitor
12%
Intraperitoneal Drug Administration
12%
Immunological Tolerance
12%
Tumor Immunity
12%
Programmed Death 1 Receptor
12%
Transfer Cell
12%
Regulatory T Cell
12%
Immunotherapy
12%
Carbon Tetrachloride
12%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Neoplasm
62%
Tumor Growth
37%
CD8 Antigen
37%
Tumor Antigen
37%
Sunitinib
37%
Mouse Model
25%
Carbon Tetrachloride
12%
Metastasis
12%
Protein Tyrosine Kinase Inhibitor
12%
Liver Cancer
12%
Intraperitoneal Injection
12%
Programmed Death 1 Receptor
12%
Immunotherapy
12%